Celldex amends 2021 Equity Plan
Celldex Therapeutics filed an amendment to its 2021 Omnibus Equity Incentive Plan, expanding available stock by 3.4 million shares. This adjustment impacts future employee retention and compensation structures.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day